Note:  information is added on this page as time goes by

Info Archive Site

Fulvic Acid

Menu Page

Index

Listed here are some abstracts of works demonstrating the therapeutic benefits of humic acids in cancer treatment.

 

Dentifricees for controlling Helobacter pylori Possibility of applying humic acids in medicine (wound healing and cancer therapy) Anti-tumor effect of humic acid and its pharmacological study.
Injection for treating rheumatic arthritis, strain or other disease in veterinary medicine Pharmacologic and toxicologic properties of humic acdis and their active profile for vet. medicine therapy Further evidence for the incompatible pharmacodynamic responses to colchicine of  malignant and benign epidermal hyperplasia in skin-tumor resistant mice.
Oxihumic acids and its use in the tratment of various conditions. Effects of sodium humate on the cells cycle and proliferation of mammalian cells. Synthetic humates in manufacture of a medicament for treatment of mucosal disease.
Effect of orally administered humic acids on the nuclei acid metabolism of ascites tumor cells in mice.    

 

Dentifricees for controlling Helobacter pylori
Patent # Kind Date Date Application
CN 1102979 A 1995 05 31 CN
1994-110886 19940321    
CN 1051223 B 2000 0412  

Abstract:

Dentifrices for controlling H.pylori (microorganism responsible for gastritis and gastric or diodenal ulcer) comprising humic acid Bi salt 0.001-0.12, metronidazole 0.001-0.23,Bi subcarbonate 0.001-0.2, Bi sub citrate 0.001-0.2, Bi subsaliceylate 0.001-0.2, and / or furaxone 0.001-0.2% with/without traditional Chinese medicines in addn. to base materials. A dentifrice containing metronidazole 0.5 sorbitol 10, glycerol 10, Na CM-cellulose 1, CaHPO4 50, SDS 3g, saccharin, flavours and water.   TOP


 

Injection for treating rheumatic arthritis, strain or other disease in veterinary medicine
Patent # Kind Date Date Application
CN 1129110 A 19960821 CN
1995-120939 1995-12/25    
CN 1059555 B 20001220  
       

Abstract:

The title injection is composed of humic acid0.05-5.0, procaine-HCL 0.02-2, NaCl 0.1-1.0, and water for injection to 100%. The injection is prepd. by dissolving humic acid in injection water, centrifugating, mixing with prcaine HCL, NaCl and addnl. injection water, stirring at 60-80', adjusting with HCL or NaOH to pH 5.0-7.0, filtering filling into vials, and sterilizing at 100' for 30min.   TOP


Pharmacologic and toxicologic properties of humic acdis and their active profile for vet. medicine therapy
Kuhnert M; Fuchs V; Golbs S    DTW. Deutsche Tierartztliche Wochenzeitschrift (1989 Jan)

Abstract:

Humic acids derive from a class of natural substances in humic substances. The chemical properties of certain defined humic acid products enable their application in diseases of the digestive system of mammals when combined with metabolic disorders, especially in rearing age. The simple administration (via feed), their exceptional safety and the absence of side effects (e.g. allergy, resistance) as well as no residue formation in animal derived products allow a broad application of these substances in veterinary medicine, even when regarding ecotoxicological aspects.      TOP


Possibility of applying humic acids in medicine (wound healing and cancer therapy)
Jurcsik, I. Lab Agrochem. Plant Physiology, Pecs, Hung.

Abstract:

Previous expts. proved that humic acids (HA, esp. hymatomolanic acid, HY) generate active oxygen of the presence of oxygen, water and radiation. Based on these expts., it was thought that this process accelerates wound healing and inhibits multiplication of malignant tumor cells. Hy can help meet the increased demand for oxygen during wound healing by producing active oxygen. Multiplication of tumor cells is restricted by the intercalation of HY mols. with DNA strands, causing hydrogen abstraction from DNA deoxyriboses (5). In addn., HY increases the respiration rate. As HA have a self-regulation mechanism for the amt. of active oxygen produced, lipid-peroxidn. was detected. Clin. tests (in the case of wound healing) and in-vitro expts. (carcinostatic lab tests) provided results that proved the above theory. In wound healing epts., 0.01%Hy shortened the healing time. HY (0.012%) reduced the reprodn. of tumor cells by 70% (HEp-2) while multiplication of HEF remains consts. DNA synthesis practically stops above a concentration of 0.004%HY. At the same time, HY had a restricting effect only above 0.2g/100ml concentration on group of cells.      TOP


Further evidence for the incompatible pharmacodynamic responses to colchicine of  malignant and benign epidermal hyperplasia in skin-tumor resistant mice.
Setala, Kai. Univ. Helsinki, Naturwissenschaften (1965), 52(18)  CAN64:222264  AN 1966:22264

Abstract:

Malignant and benign hyperplasia was provoked on the backs of mice. These and normal animals were exposed to an Me2CO soln. of colchicine (I), alone and in combination with phlorizin (II) or humic acid (III) prepn. The examination of the biopsies by cytologic, light-, polarization-, and electron microscopic methods, revealed that the combined exposure did not alter the effects of I (cf. preceding abstract). The addition of II or III to benign epidermal hyperplasia decreased the I effect. Normal epidermis responded in a similar manner. Neither II or III enhanced the effect of I on malignant hyperplasia. There was a qual. difference between the susceptibility of the receptors of malignant and non-malignant cells. Radiodynamic and pharmacodynamic responses cannot be used as reciprocal models of general reactivity nor as a common determinant in the evaluation of efficacy of a given anticancer measure.


Anti-tumor effect of humic acid and its pharmacological study.
Fu, Maiwu; Zhang, Lisheng, Lanpin et al Chinese Med. Sci. Peop. Rep. of China. YHTPAD ISSN:0512-7343 , CAN 96:79555 AN 1982:79555

Abstract:

The antitumor effect of 2 different humic acid preparations was studied. Both inhibited the growth of mouse S-180 sarcoma and hepatoma. One preparation inhibited mouse uterine cervical cancer U14, whereas the other was not effective. Neither preparation affected the phagocytic activity of the mouse reticuloendothelial system, but both markedly reduced spleen.wt. and the formation of splenic rosette cells and hemagglutinating antibodies. Neither preparation influenced the content and synthesis of DNA, but both markedly decreased the content and synthesis of RNA, in S-180 cells    TOP


Oxihumic acids and its use in the tratment of various conditions.
Patent # Kind Date Date Application
WO 2000016786 A2 20000330 WO
1999-IB1569 19990922    
WO 2000016786 A3 20000608  

Abstract:

A pharmaceutical compound comprising an oxihumic acid salt, ester or derivatives thereof as an active ingredient is disclosed. The compound. is preferably administered orally for stimulating lymphocytes in a human, animal or bird. It may be used in treating viral and bacterial infections, HIV infections, opportunistic diseases, inflammation, pain and fever, cancer growth and diseases associated with viral infection and a depressed immune system. A number of pharmacological examples were given including interleukin 10 production by oxihumate treated lymphocytes, increased antibody production against Newcastle disease in chickens treated with oxihumate, TNF production by oxihumate treated lymphocytes, and antiviral activity of oxihumate against HSV-1 and coxsackie virus type 1 in vitro.

 

TOP


Effects of sodium humate on the cells cycle and proliferation of mammalian cells.
Hofmanova J., Kozubik A., Hola J., et al Institude of Biophysics Acad. of Sciences Czech Republic.
Biochem. Metab. (1999) CODEN: KBMEFQ ISSN: 1210-7921  

Abstract:

It was demonstrated that sodium humate (HUNa) prepared from natural humic acids, suppressed proliferation of four mammalian cell lines of different origin in vito in a concentration dependent manner without decreasing cell viability. Incubation with HUNa caused accumulation of cells in the G0/G1 phase of the cell cycle as determined by flow cytometry. Both these effects were found to be reversible. Similar results were obtained in vito using most lymphosarcoma cells growing as an ascit in the pertoneal cavity of mice treated with HUna. Moreover, pre-treatment of these cells with HUna significantly decreased their ability for form metastatic infiltration in the mouse liver after i.v. administration. The mechanism(s) of HUNa effects are discussed, which could be connected with its special chemical properties, such as great surface activities, redox properties, absorption ability and/or free radical content. These properties can all effect predominantly cell surface and thus the cell response to external signals. The author's findings can be important both from ecotoxicological and therapeutic points of view.

TOP


Synthetic humates in manufacture of a medicament for treatment of mucosal disease.
Patent # Kind Date Date Application
EP 656208 A2 19950607 EP
1994-113498 19940830    
Kuehnert Manfred, Haase Anton F. , Kleffner Hans Werner  Reutgerswerke AG, Germany

Abstract:

Synthetic humates, prepd. by oxidn. of polyhydric phenolic compds. are useful in manuf. of drug compounds for oral administration for treatment of irritation and inflammation of gastric, intestinal, respiratory and reproductive tract mucosa in human and veterinary medicine. Thus lavage of bovine uterus with 2L 4% Na humate solution prepared by oxidation of hydrquinone, 4 times at 12 h intervals after a difficult birth accelerated regeneration of the uterus.

 

TOP


Effect of orally administered humic acids on the nuclei acid metabolism of ascites tumor cells in mice.
Zsindley, A.; Hofmann R.; Klocking R.   Biokem.Intez., Orvostud. EGY., Debrecen, Hung. Acta Biol. Debrecina (1973)
CODEN: ABIDAO   CAN 81:114748    

Abstract:

Humic acids (40mg) administered orally to mice bearing Crocker sarcoma 180 or Nemeth-Kellner ascites lymphoma for 5 days decreased the amount of ascites fluid and the tumor cell no. The acids also decreased the amount of DNA and RNA in tumor tissue and altered the amino acid compn. Thymine was increased and adenine was decreased in DNA, and adenine was increased in RNA


 
Patent # Kind Date Date Application
       
       
       
       

Abstract:

 

TOP


 
       
       
       
 

  Back to Fulvic/Humic Index       Back to O2xygen Index       Back to Colloidal Silver Index